Nivalis Therapeutics' Merger

Nivalis Therapeutics raised a round of funding on July 21, 2017. Investors include Alpine Immune Sciences.

Nivalis Therapeutics, formerly N30Pharma, is developing a novel class of disease modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule wit…

Articles about Nivalis Therapeutics' Merger: